Rigel Pharmaceuticals, Inc.

395 articles with Rigel Pharmaceuticals, Inc.

• 

  Top 10 Biotech Bay Companies by Revenue

  11/18/2019

  The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.

• Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

  11/15/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion for Rigel's Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib) for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.

• Rigel to Present at Jefferies 2019 London Healthcare Conference

  11/13/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:40pm GMT. 

• Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition

  11/7/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition to be held December 7-10, 2019, in Orlando, FL.

• Rigel Announces Third Quarter 2019 Financial Results

  11/5/2019

  Advances development pipeline with new RIP1 inhibitor program initiating a Phase 1 study and positive in-human data from IRAK1/4 inhibitor program

• Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results

  10/29/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2019 financial results after market close on Tuesday, November 5, 2019.

• Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call

  10/23/2019

  Rigel Pharmaceuticals, Inc. provided a business update that will be discussed in more detail on the company's investor and analyst call

• Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

  10/18/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib)

• Rigel to Host Investor and Analyst Call on October 23, 2019

  10/16/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced that it will host a conference call and webcast for investors and analysts on Wednesday, October 23, 2019, at 10:00am Eastern Time.

• Rigel Secures Credit Facility for Up to $60 Million

  10/2/2019

  Rigel Pharmaceuticals, Inc. announced that it has entered into a $60 million term loan credit facility with MidCap Financial.

• Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

  9/23/2019

  Rigel Pharmaceuticals, Inc. announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd., has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia.

• Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

  8/28/2019

  The panel entitled "The Fascinating World of 'Benign' Hematology" will be held on Thursday, September 5, 2019 from 8:00 am – 8:40 am Eastern Time.

• Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update

  8/6/2019

  TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million

• Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results

  7/30/2019

  Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6, 2019.

• Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)

  6/13/2019

  Rigel Pharmaceuticals, Inc. announced that it will present data on fostamatinib disodium hexahydrate in two posters at the 24th Congress of the European Hematology Association in Amsterdam, The Netherlands, on June 13-16, 2019.

• Rigel to Present at Jefferies 2019 Healthcare Conference

  5/31/2019

  Rigel Pharmaceuticals, Inc. announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2:30pm EDT.

• Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia

  5/16/2019

  Announces resignation of Chief Medical Officer effective August 31, 2019

• Rigel Announces First Quarter 2019 Financial Results and Provides Company Update

  5/7/2019

  Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019, including sales of TAVALISSE®, for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

• Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update

  4/30/2019

  Rigel Pharmaceuticals, Inc. announced that it will report its first quarter 2019 financial results after market close on Tuesday, May 7, 2019.

• Rigel Welcomes Jane Wasman to Board of Directors

  3/26/2019

  Peter S. Ringrose, Ph.D. Retires from Board Position